Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Uterine Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Cancer 1Meningeal Carcinomatosis 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Paclitaxel 6pembrolizumab 3Cisplatin 3Carboplatin 3Biopsy 3adavosertib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Fulvestrant 2Doxorubicin 2ulixertinib 1tucatinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1selinexor 1sapanisertib 1sacituzumab govitecan 1relugolix 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1niraparib 1larotrectinib 1ipatasertib 1erdafitinib 1dostarlimab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Neoplasms × adavosertib × 1 year × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03668340 2026-01-12

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
49 enrolled
Gynecologic

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡